Literature DB >> 21744183

Active immunological profile is associated with systemic Sjögren's syndrome.

Clothilde Martel1, Guillaume Gondran, David Launay, Fabrice Lalloué, Sylvain Palat, Marc Lambert, Kim Ly, Veronique Loustaud-Ratti, Holly Bezanahary, Eric Hachulla, Marie Odile Jauberteau, Elisabeth Vidal, Pierre Yves Hatron, Anne Laure Fauchais.   

Abstract

BACKGROUND: The aim of this paper was to study the evolution of primary Sjögren's syndrome (pSS) immunological profile, its impact on pSS activity and long-term evolution in a bicentric cohort of French patients with pSS (n = 445, mean age 53.6 ± 14 years, mean follow-up 76.1 ± 51 months).
METHODS: This is a retrospective cohort study.
RESULTS: Two hundred twelve patients were Sjögren's syndrome A (SSA) positive, and 131 were both SSA and Sjögren's syndrome B (SSB) positive. Sixty-eight patients (15%) had cryoglobulinemia. Active systemic profile (i.e., hypergammaglobulinemia, rheumatoid factor (RF), and anti-Sjögren's syndrome A (anti-SSA), anti-Sjögren's syndrome B (anti-SSB) positivity), associated with multisystemic involvement, leads to an increased utilization of corticosteroid and hydroxychloroquine. Multivariate analysis pointed out independent statistical association between hypergammaglobulinemia, anti-SSA, anti-SSB, and RF. Cryoglobulinemia is associated with multi-systemic involvement, lymphoma, and pSS-related death.
CONCLUSION: The subset of patients with active immunological profile is characterized by systemic complications leading to immunosuppressive drug utilization and polyclonal B-cell activation profile.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21744183     DOI: 10.1007/s10875-011-9553-3

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long-term study.

Authors:  K Asmussen; V Andersen; G Bendixen; M Schiødt; P Oxholm
Journal:  J Intern Med       Date:  1996-06       Impact factor: 8.989

3.  [Primary Sjögren's syndrome: clinical and immunologic study of 80 patients].

Authors:  M Ramos; R Cervera; M García-Carrasco; C Miret; F J Muñoz; G Espinosa; J Font; M Ingelmo
Journal:  Med Clin (Barc)       Date:  1997-05-03       Impact factor: 1.725

4.  Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients.

Authors:  Anne-Laure Fauchais; Bali Ouattara; Guillaume Gondran; Fabrice Lalloué; Daniel Petit; Kim Ly; Marc Lambert; David Launay; Véronique Loustaud-Ratti; Holly Bezanahari; Eric Liozon; Eric Hachulla; Marie-Odile Jauberteau; Elisabeth Vidal; Pierre-Yves Hatron
Journal:  Rheumatology (Oxford)       Date:  2010-03-18       Impact factor: 7.580

5.  Xerostomia in Sjögren's syndrome. Evaluation by sequential salivary scintigraphy.

Authors:  G L Schall; L G Anderson; R O Wolf; J R Herdt; T M Tarpley; N A Cummings; L S Zeiger; N Talal
Journal:  JAMA       Date:  1971-06-28       Impact factor: 56.272

6.  Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity.

Authors:  E L Alexander; F C Arnett; T T Provost; M B Stevens
Journal:  Ann Intern Med       Date:  1983-02       Impact factor: 25.391

7.  Primary Sjögren's syndrome in the North East of England: a long-term follow-up study.

Authors:  B K Davidson; C A Kelly; I D Griffiths
Journal:  Rheumatology (Oxford)       Date:  1999-03       Impact factor: 7.580

Review 8.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

9.  Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients.

Authors:  Manuel Ramos-Casals; Juan-Manuel Anaya; Mario García-Carrasco; José Rosas; Albert Bové; Gisela Claver; Luis-Aurelio Diaz; Carmen Herrero; Josep Font
Journal:  Medicine (Baltimore)       Date:  2004-03       Impact factor: 1.889

10.  Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects.

Authors:  Evangelia Baimpa; Issa J Dahabreh; Michael Voulgarelis; Haralampos M Moutsopoulos
Journal:  Medicine (Baltimore)       Date:  2009-09       Impact factor: 1.889

View more
  22 in total

Review 1.  Autoantibodies in Sjögren's Syndrome.

Authors:  Anum Fayyaz; Biji T Kurien; R Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

2.  Clinical and serological characteristics of seronegative primary Sjögren's syndrome: a comparative study.

Authors:  Veli Yazisiz; Bengisu Aslan; Funda Erbasan; İsmail Uçar; Tahir Saygin Öğüt; Mustafa Ender Terzioğlu
Journal:  Clin Rheumatol       Date:  2020-06-05       Impact factor: 2.980

3.  Spontaneous loss of tolerance of autoreactive B cells in Act1-deficient rheumatoid factor transgenic mice.

Authors:  Natalia V Giltiay; Yi Lu; Jaime L Cullen; Trine N Jørgensen; Mark J Shlomchik; Xiaoxia Li
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

4.  Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement.

Authors:  Andreina Manfredi; Marco Sebastiani; Stefania Cerri; Giulia Cassone; Pietrantonio Bellini; Giovanni Della Casa; Fabrizio Luppi; Clodoveo Ferri
Journal:  Clin Rheumatol       Date:  2017-03-21       Impact factor: 2.980

5.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30

6.  Pain severity and neuropathic pain symptoms in primary Sjögren's syndrome: a comparison study of seropositive and seronegative Sjögren's syndrome patients.

Authors:  Barbara M Segal; Brian Pogatchnik; Lisa Henn; Kyle Rudser; Kathy Moser Sivils
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-08       Impact factor: 4.794

7.  Younger patients with primary Sjögren's syndrome are more likely to have salivary IgG anti-muscarinic acetylcholine receptor type 3 antibodies.

Authors:  K Jayakanthan; J Ramya; Santosh Kumar Mandal; P Sandhya; M Gowri; Debashish Danda
Journal:  Clin Rheumatol       Date:  2016-01-26       Impact factor: 2.980

Review 8.  Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.

Authors:  Maria B Nishishinya; Claudia A Pereda; Santiago Muñoz-Fernández; José M Pego-Reigosa; Iñigo Rúa-Figueroa; José-Luis Andreu; Mónica Fernández-Castro; José Rosas; Estibaliz Loza Santamaría
Journal:  Rheumatol Int       Date:  2014-06-05       Impact factor: 2.631

9.  Persistent serological activity in primary Sjögren's syndrome.

Authors:  Jorge López-Morales; Daniel Cortes-Muñoz; Miguel Astudillo-Ángel; Gabriela Hernández-Molina
Journal:  Clin Rheumatol       Date:  2019-12-14       Impact factor: 2.980

Review 10.  Diagnostic performance of serology against histologic assessment to diagnose Sjogren's syndrome: a systematic review.

Authors:  Luiz Claudio Viegas-Costa; Reid Friesen; Carlos Flores-Mir; Timothy McGaw
Journal:  Clin Rheumatol       Date:  2021-06-17       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.